Journal Logo

Erratum

Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study: Erratum

doi: 10.1097/TXD.0000000000001259
  • Open

The authors of the article listed below, which published July 9, 2021 in Transplantation Direct, note that Figure 2B was not properly displayed. The solid red, blue dashed, and green dotted lines do not correspond to the description of graft survival rates per treatment arm cited in the manuscript body. The correct figure is shown below. The authors also note that the text reference to Cox proportional hazards model analysis of HCV status incorrectly states the HR value as 2.00. The HR value is 2.01, as cited in Table 5. The text should read as follows:

Cox proportional hazards model analysis of overall patient survival (Table 5) showed that patients with a positive baseline HCV status had a higher hazard of death than patients with a negative baseline HCV status (HR, 2.01; 95% CI, 1.47-2.74).

REFERENCE

Friman S, Tisone G, Nevens F, et al. Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study. Transplantation Direct. 2021;7(8):e722; doi: 10.1097/TXD.0000000000001166. Published online July 9, 2021.
    © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.